Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 6/20 | 0.49 |
| ▸ | HRH1 | P35367 | 6/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252763 | 1.00 | HRH2 (0.49) | HRH2HRH1GPR119DRD3L3MBTL1 | |
| SCHEMBL7249491 | 0.87 | HRH2 (0.56) | HRH2HRH1GPR119 | |
| SCHEMBL7245710 | 0.87 | HRH2 (0.56) | HRH2HRH1GPR119 | |
| SCHEMBL491549 | 0.81 | KDM4E (0.57) | HRH2HRH1L3MBTL1MEN1KMT2A | |
| SCHEMBL7978391 | 0.79 | DRD3 (0.41) | HRH2HRH1DRD3L3MBTL1MEN1 | |
| SCHEMBL7978394 | 0.79 | HRH2 (0.42) | HRH2HRH1DRD3L3MBTL1MEN1 | |
| SCHEMBL7252027 | 0.79 | L3MBTL1 (0.51) | HRH2HRH1DRD3L3MBTL1GAA | |
| SCHEMBL7248835 | 0.78 | HRH2 (0.45) | HRH2HRH1DRD3L3MBTL1MEN1 | |
| SCHEMBL20425432 | 0.77 | DRD3 (0.55) | GPR119DRD3L3MBTL1MAPT | |
| SCHEMBL16825660 | 0.76 | DRD3 (0.54) | HRH2HRH1GPR119DRD3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001066534-A2 | CYCLIC AND BICYCLIC DIAMINO HISTAMINE-3 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | disclosed |